Metastatic Pancreatic Adenocarcinoma Clinical Trial
Official title:
Weight Loss in Patients With Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl
Verified date | August 2023 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Status | Active, not recruiting |
Enrollment | 22 |
Est. completion date | October 1, 2024 |
Est. primary completion date | October 26, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - GROUP 1 (Telotristat ethyl treatment group): Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. - GROUP 1 (Telotristat ethyl treatment group): Weight loss of 10% or more. - GROUP 1 (Telotristat ethyl treatment group): Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 within 14 days prior to registration. - GROUP 1 (Telotristat ethyl treatment group): Histologic or cytological diagnosis of recurrent or metastatic pancreas adenocarcinoma (PDAC) who present for first line chemotherapy treatment for metastatic disease. - GROUP 1 (Telotristat ethyl treatment group): Advanced stage pancreas cancer (recurrent/metastatic). - GROUP 1 (Telotristat ethyl treatment group): Measurable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI). - GROUP 1 (Telotristat ethyl treatment group): Prior systemic therapy (adjuvant or neoadjuvant setting are acceptable) if disease progressed or recurred within at least 3 months after treatment. - GROUP 1 (Telotristat ethyl treatment group): Estimated life expectancy of > 12 weeks, as assessed by the site investigator. - GROUP 1 (Telotristat ethyl treatment group): If sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods) due to unknown risk of teratogenicity. - GROUP 1 (Telotristat ethyl treatment group): Hemoglobin = 8 g/dL (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Absolute Neutrophil Count (ANC) = 1,500/mm³ (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Platelet Count (PLT) = 100,000/mm³ (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Creatinine = 1.5 mg/dL (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Albumin = 2 g/dL (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Bilirubin = 1.5 mg/dL (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Aspartate aminotransferase (AST) = 3 x upper limit of normal (ULN) or < 5 x ULN in the setting of liver metastases (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Alanine aminotransferase (ALT) = 3 x ULN or < 5 x ULN in the setting of liver metastases (obtained within 7 days prior to registration). - GROUP 1 (Telotristat ethyl treatment group): Prior radiation is allowed if happened more than 2 weeks of enrollment. - GROUP 2 (Non-Telotristat ethyl group): Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. - GROUP 2 (Non-Telotristat ethyl group): Stable weight or loss of < 10% by history. - GROUP 2 (Non-Telotristat ethyl group): ECOG Performance Status of 0-2 within 14 days prior to registration. - GROUP 2 (Non-Telotristat ethyl group): Histologic or cytological diagnosis of locally advanced unresectable, recurrent/metastatic PDAC who present for first line chemotherapy treatment for metastatic disease. - GROUP 2 (Non-Telotristat ethyl group): Advanced stage PDAC (locally advanced unresectable/recurrent/metastatic). - GROUP 2 (Non-Telotristat ethyl group): Prior systemic therapy (adjuvant or neoadjuvant setting are acceptable) if disease progressed or recurred within at least 3 months after treatment. - GROUP 2 (Non-Telotristat ethyl group): Estimated life expectancy of > 12 weeks, as assessed by the site investigator. - GROUP 2 (Non-Telotristat ethyl group): Prior radiation is allowed if happened more than 2 weeks of enrollment. Exclusion Criteria: - GROUP 1 (Telotristat ethyl treatment group): Subjects with histology other than adenocarcinoma. Examples include: neuroendocrine tumors, acinar cell cancer, sarcoma or lymphoma of the pancreas. - GROUP 1 (Telotristat ethyl treatment group): Ongoing or active infection. - GROUP 1 (Telotristat ethyl treatment group): Symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia. Symptomatic heart failure (New York Heart Association [NYHA] Class II-IV). - GROUP 1 (Telotristat ethyl treatment group): Acute or sub-acute intestinal obstruction. - GROUP 1 (Telotristat ethyl treatment group): Ascites. - GROUP 1 (Telotristat ethyl treatment group): Documented and/or symptomatic or known brain or leptomeningeal metastases. - GROUP 1 (Telotristat ethyl treatment group): Severely immune-compromised (other than being on steroids) including known human immunodeficiency virus (HIV) infection. - GROUP 1 (Telotristat ethyl treatment group): Concurrent active malignancy, other than adequately treated non-melanoma skin cancer, other noninvasive carcinoma, or in situ neoplasm. A subject with previous history of malignancy is eligible if he/she has been disease-free for > 3 years. - GROUP 1 (Telotristat ethyl treatment group): Breast-feeding or pregnant. Serum pregnancy test for women of child-bearing potential must be performed within 7 days prior to first dose of study treatment. - GROUP 1 (Telotristat ethyl treatment group): Prior autologous or allogeneic organ or tissue transplantation. - GROUP 1 (Telotristat ethyl treatment group): Known allergy to any of the treatment components. - GROUP 1 (Telotristat ethyl treatment group): Have any condition that does not permit compliance with the study schedule including psychological, geographical, or medical. - GROUP 1 (Telotristat ethyl treatment group): Not able to swallow. Inability to take oral medications. - GROUP 1 (Telotristat ethyl treatment group): Patients with chronic constipation. - GROUP 2 (Non-Telotristat ethyl group): Subjects with histology other than adenocarcinoma. Examples include: neuroendocrine tumors, acinar cell cancer, sarcoma or lymphoma of the pancreas. - GROUP 2 (Non-Telotristat ethyl group): Ongoing or active infection. - GROUP 2 (Non-Telotristat ethyl group): Symptomatic congestive heart failure, unstable angina or arrhythmia. Symptomatic heart failure (NYHA Class II-IV). - GROUP 2 (Non-Telotristat ethyl group): Acute or sub-acute intestinal obstruction. - GROUP 2 (Non-Telotristat ethyl group): Severely immune-compromised (other than being on steroids) including known HIV infection. |
Country | Name | City | State |
---|---|---|---|
United States | Emory Saint Joseph's Hospital | Atlanta | Georgia |
United States | Emory University Hospital Midtown | Atlanta | Georgia |
United States | Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | Lexicon Pharmaceuticals, National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight stability | Weight stability will be documented as percent weight change at 3 months compared to baseline. | Baseline up to 3 months after study start | |
Secondary | Change in serum 5-hydroxyindoleacetic acid (5-HIAA) levels | The change will be summarized as mean and standard deviation. | Baseline up to 4 months after study start | |
Secondary | Change in 24-hr urine 5-hydroxyindoleacetic acid (5-HIAA) levels | The change will be summarized as mean and standard deviation. | Baseline up to 4 months after study start | |
Secondary | Mid arm circumference (MAC) measured in inches | Mid arm circumference (MAC) will be reviewed on cross sectional imaging and will be assessed with imaging guided measurements of the psoas and rectus abdominis muscle. | Up to 2 years after study start | |
Secondary | Quality of life (QOL) | Quality of life (QOL) will be assessed by the Obesity Related Quality of Life (OWL-QOL)-17 questionnaire. | Up to 2 years after study start | |
Secondary | Blood serotonin levels | Blood serotonin levels will be compared in the 2 groups. | Up to 2 years after study start | |
Secondary | Response rate (RR) | Response rate (RR) will be assessed per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, in patients receiving telotristat ethyl (Group 1). | Up to 2 years after study start | |
Secondary | Median overall survival (MOS) | Median overall survival (MOS) will be measured using the Kaplan-Meier method. | Up to 2 years after study start | |
Secondary | Duration of response | Duration of response will be estimated from time of documentation of response to time of progression and will be evaluated by computed tomography/magnetic resonance imaging scans of the organ(s) with the target lesion(s) based on RECIST criteria. | Up to 2 years after study start |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01964287 -
First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
|
Phase 1/Phase 2 | |
Completed |
NCT02826486 -
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)
|
Phase 2 | |
Active, not recruiting |
NCT04524702 -
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02890355 -
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04652206 -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04132505 -
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT00998322 -
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04514497 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02562898 -
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Completed |
NCT01896869 -
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03337087 -
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02677038 -
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06381154 -
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02985125 -
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05383352 -
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
|
Phase 1 | |
Completed |
NCT03943667 -
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02436668 -
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
|
Phase 3 | |
Completed |
NCT01360853 -
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
|
Phase 3 |